Literature DB >> 22020667

Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus.

Z Zhang1, L Li, M Yang, H Liu, G Boden, G Yang.   

Abstract

BACKGROUND: Nesfatin-1, which is derived from nucleobindin2 (NUCB2), has been recently identified as a novel satiety regulator. However, its pathophysiological role in humans remains unknown. The aim of the present study was to investigate plasma nesfatin-1 levels and the association between plasma nesfatin-1 levels and various metabolic parameters in humans.
MATERIALS AND METHODS: 74 subjects with newly diagnosed type 2 diabetes mellitus (nT2DM), 73 subjects with impaired glucose tolerance (IGT) and 73 subjects with normal glucose tolerance (NGT) were enrolled in this study. Plasma nesfatin-1 levels were measured by a commercially available enzyme- linked immunosorbent assay.
RESULTS: Plasma nesfatin-1 levels were elevated in subjects with both nT2DM and IGT compared to controls (1.91±0.79 and 1.80±0.80 vs. 1.41±0.58 μ g/L, P<0.05 or P<0.01 ). Simple regression analysis showed that in subjects with IGT and nT2DM, plasma nesfatin-1 correlated positively with body mass index (BMI), hemoglobin A1c (HbA(1c)), fasting blood glucose (FBG), 2 h blood glucose after a glucose load (2hPBG), fasting plasma insulin (FINS) and the homeostasis model assessment of insulin resistance (HOMA(-IR)). Multivariate logistic regression analysis revealed that plasma nesfatin-1 was significantly associated with IGT and nT2DM, even after controlling for differences in BMI.
CONCLUSION: Plasma nesfatin-1 concentrations were found to be elevated in subjects with both IGT and nT2DM and to be related with several clinical parameters known to be associated with insulin resistance. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020667     DOI: 10.1055/s-0031-1286339

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  24 in total

1.  Islet β-cell-produced NUCB2/nesfatin-1 maintains insulin secretion and glycemia along with suppressing UCP-2 in β-cells.

Authors:  Yifei Yang; Boyang Zhang; Masanori Nakata; Jun Nakae; Masatomo Mori; Toshihiko Yada
Journal:  J Physiol Sci       Date:  2019-06-21       Impact factor: 2.781

2.  Nesfatin-1 and other hormone alterations in polycystic ovary syndrome.

Authors:  Rulin Deniz; Bilgin Gurates; Suleyman Aydin; Husnu Celik; Ibrahim Sahin; Yakup Baykus; Zekiye Catak; Aziz Aksoy; Cihan Citil; Sami Gungor
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

3.  Nesfatin-1 and Vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome.

Authors:  Figen Kir Sahin; Serap Baydur Sahin; Ulku Mete Ural; Medine Cumhur Cure; Senol Senturk; Yesim Bayoglu Tekin; Gulsah Balik; Erkan Cure; Suleyman Yuce; Aynur Kirbas
Journal:  Bosn J Basic Med Sci       Date:  2015-07-09       Impact factor: 3.363

Review 4.  Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome.

Authors:  Tuba Tekin; Betul Cicek; Nurefsan Konyaligil
Journal:  Eurasian J Med       Date:  2019-08-19

5.  Expression and function of nesfatin-1 are altered by stage of the estrous cycle.

Authors:  Alicia T Pate; Abigayle L Schnell; Teresa A Ennis; Willis K Samson; Gina L C Yosten
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-05-29       Impact factor: 3.619

6.  Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome.

Authors:  Esra Nur Ademoglu; Suheyla Gorar; Ayse Carlıoglu; Havva Yazıcı; Fatma Dilek Dellal; Zehra Berberoglu; Derya Akdeniz; Sema Uysal; Feridun Karakurt
Journal:  J Endocrinol Invest       Date:  2014-06-12       Impact factor: 4.256

Review 7.  Multi-functional peptide hormone NUCB2/nesfatin-1.

Authors:  Suleyman Aydin
Journal:  Endocrine       Date:  2013-03-23       Impact factor: 3.633

8.  Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome.

Authors:  Peng Shen; Yingying Han; Bo Cai; Yu Wang
Journal:  Sleep Breath       Date:  2014-07-24       Impact factor: 2.816

Review 9.  The role of nesfatin-1 in the regulation of food intake and body weight: recent developments and future endeavors.

Authors:  A Stengel; M Mori; Y Taché
Journal:  Obes Rev       Date:  2013-08-27       Impact factor: 9.213

10.  Neural circuitry underlying the central hypertensive action of nesfatin-1: melanocortins, corticotropin-releasing hormone, and oxytocin.

Authors:  Gina L C Yosten; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-03-05       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.